News

MSK-IMPACT™ Is the First Tumor-Profiling Multiplex Panel Authorized by the FDA, Setting a New Pathway to Market for Future Oncopanels

New York, NY, Wednesday, November 15, 2017 – The US Food and Drug Administration (FDA) announced today the authorization of MSK-IMPACT™ (which stands for integrated mutation profiling of actionable cancer targets), a high throughput, targeted-DNA-sequencing panel for somatic mutations. Created by the Department of Pathology at Memorial Sloan Kettering Cancer Center (MSK), MSK-IMPACT is a […]

Memorial Sloan Kettering Is Expanding Its Footprint in Long Island

Uniondale, NY, Thursday, October 19, 2017 – Memorial Sloan Kettering, one of the nation’s top cancer treatment and research institutions, is expanding its reach on Long Island with a new 114,000-square-foot freestanding cancer treatment center in Nassau County. Once complete, MSK Nassau will house the area’s most comprehensive cancer care program, centrally located and staffed […]

Norwalk Hospital and Memorial Sloan Kettering Launch Unique Cancer Care Collaboration

Norwalk, Connecticut, Monday, October 16, 2017 – Norwalk Hospital and Memorial Sloan Kettering Cancer Center (MSK) today announced MSK Physicians at Norwalk Hospital, a new cancer care collaboration that will integrate MSK medical and radiation oncologists and care practices with the existing cancer program at the C. Anthony and Jean Whittingham Cancer Center at Norwalk […]

Cancer Immunologist Andrea Schietinger of Sloan Kettering Institute Honored with Prestigious NIH Director’s New Innovator Award Share Email Print

New York, NY, Thursday, October 5, 2017 – Cancer immunologist Andrea Schietinger, PhD, of the Sloan Kettering Institute (SKI) at Memorial Sloan Kettering (MSK) has been honored with the prestigious National Institutes of Health (NIH) Director’s New Innovator Award. Dr. Schietinger was selected as a winner for her groundbreaking work in immune responses to cancer, […]

Novant Health expands cancer specialists in Charlotte

CHARLOTTE, NC – September 17, 2017 – Novant Health has again increased patient access to cancer services by adding three medical oncologists to its team of cancer experts. Drs. Deborah Ann Bradley, Lilian Thomas-Harris and Obiageli Ogbata have recently joined Novant Health Cancer Specialists and are accepting new patients in the Charlotte office. “The addition […]

LYNPARZA Receives Additional and Broad Approval in the U.S. for Ovarian Cancer

LYNPARZA’s New Tablet Formulation Approved as Maintenance Treatment for Women With Platinum-Sensitive Recurrent Ovarian Cancer Regardless of BRCA-Mutation Status LYNPARZA Tablets Also Indicated in BRCA-Mutated Ovarian Cancer Beyond the Third-Line Setting Newly-Approved Tablet Formulation Means Improved Patient Convenience August 17, 2017 KENILWORTH, N.J.–(BUSINESS WIRE)–AstraZeneca and Merck & Co., Inc. (NYSE:MRK), known as MSD outside the […]

Pfizer Receives U.S. FDA Approval for Besponsa® (Inotuzumab Ozogamicin)

BESPONSA is the first and only CD22-directed antibody-drug conjugate indicated for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia NEW YORK – August 17, 2017 – Pfizer Inc. (NYSE:PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved BESPONSA® (inotuzumab ozogamicin) for the treatment of adults with relapsed […]

AstraZeneca and Merck Establish Strategic Oncology Collaboration

Collaboration Aims to Maximize the Potential of PARP and MEK Inhibitors in Combination with PD-L1/PD-1 Medicines, Based on Growing Scientific Evidence That These Combinations Offer New Potential for the Treatment of a Range of Tumor Types AstraZeneca and Merck Will Independently Develop and Commercialize LYNPARZA and Potential Medicine Selumetinib in Combinations with Companies’ Respective PD-L1/PD-1 […]

Pfizer Announces Positive Top-line Results From the Comparative Reflections B7391003 Study for PF-06439535, a Potential Biosimilar to Avastin®1 (Bevacizumab)

Results demonstrate equivalence in objective response rate in patients with advanced non-squamous non-small cell lung cancer NEW YORK, July 24, 2017 – Pfizer Inc. (NYSE:PFE) today announced that the REFLECTIONS B7391003 study, a comparative, confirmatory safety and efficacy study of PF-06439535 versus Avastin® (bevacizumab), met its primary objective. PF-06439535 is being developed by Pfizer as […]

Roche launches imCORE, a global network of cancer immunotherapy centers of excellence

Research network of 21 academic centers from around the world to access and share technology, data and expertise to advance the science of cancer immunotherapy Roche will invest up to 100 million Swiss Francs to support basic and clinical research collaborations within the imCORE Network Basel, 15 November 2016 – Roche (SIX: RO, ROG; OTCQX: […]

‹ 1 2 3 4 ›»